The increasing incidence of obesity has been a concern for several years. Therefore, researchers worldwide continue to search for an effective method for reversing obesity. In a similar attempt, scientists have successfully demonstrated the safety and efficacy of semaglutide for treating obesity. The USFDA has approved semaglutide for the treatment of chronic weight management in adults with obesity (BMI ≥ 27 kg/m 2 ) or at least one weight-related condition with a BMI of 30 kg/m 2 .
The treatment should be combined with a reduced-calorie diet and increased physical activity. The dose of semaglutide must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly. This is crucial to avoid the gastrointestinal side effects of the drug. Prescription information Semaglutide mimics glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake.…
